When BCMA-directed therapy is not an option, how should we treat late relapse? episode artwork

EPISODE · May 24, 2021 · 3 MIN

When BCMA-directed therapy is not an option, how should we treat late relapse?

from Multiple Myeloma Hub

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not an option, how should we treat late relapse?Leleu discusses three alternatives to anti-B-cell maturation antigen (BCMA) directed therapies, including alternative drugs (provided the patient is nonrefractory), enrolment to clinical trials investigating new treatments, and the use of developing agents administered in the context of compassionate use. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published May 24, 2021

Embed this episode

NOW PLAYING

When BCMA-directed therapy is not an option, how should we treat late relapse?

0:00 3:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Multiple Myeloma Hub?

This episode is 3 minutes long.

When was this Multiple Myeloma Hub episode published?

This episode was published on May 24, 2021.

Can I download this Multiple Myeloma Hub episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!